As shown in a post hoc analysis of RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy), ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), and ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trials, VKA use in Asian patients with atrial fibrillation (AF) is associated with a higher risk of bleeding when compared with non-Asian patients [109]. Here, F10 is linked to stroke disorder.